RSSMorphotek®, Inc. Announces Research Agreement with The University of Pennsylvania to Develop Oncology Therapeutic Antibody Candidates
Dec 23
Education, University Abramson Comprehensive Cancer Center, antibodies, antibody products, Associate, biopharmaceutical company specializing, Boston Inc., cancer, cancer therapies, cancers, clinical development group, Eisai Co., Eisai Co. Ltd., Eisai Corporation of North America, Eisai Inc., Eisai Medical Research Inc., Eisai Research Institute of Boston, First Boston Inc, gene evolution, gene evolution technology, infectious disease, inflammation, Ltd., Morphotek Inc, Nicholas C. Nicolaides, North America, Pennsylvania, pharmaceutical manufacturing machinery, Pharmaceutical Product Development, radiation, the University of Pennsylvania, the University of Pennsylvania School of Medicine and Co-Program, treatment of cancer, tumor, tumors, United States, University of Pennsylvania, Wafik S. El-Deiry No Comments
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that it has signed a Sponsored Research Agreement with The University of Pennsylvania to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors. Hypoxia is a condition in which suboptimal oxygen concentrations exist in [...]